The burgeoning landscape of novel treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://saulcxuo134046.wikimidpoint.com/6384528/retatrutide_vs_tirzepatide_a_comparative_analysis